80 related articles for article (PubMed ID: 16129128)
1. Life expectancy and the value of early detection.
Howard DH
J Health Econ; 2005 Sep; 24(5):891-906. PubMed ID: 16129128
[TBL] [Abstract][Full Text] [Related]
2. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
3. Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages.
Ross KS; Guess HA; Carter HB
Urology; 2005 Nov; 66(5):1038-42. PubMed ID: 16286120
[TBL] [Abstract][Full Text] [Related]
4. Comparing risks and benefits of colorectal cancer screening in elderly patients.
Ko CW; Sonnenberg A
Gastroenterology; 2005 Oct; 129(4):1163-70. PubMed ID: 16230070
[TBL] [Abstract][Full Text] [Related]
5. Diminishing returns? The costs and benefits of improving health.
Murphy K; Topel R
Perspect Biol Med; 2003; 46(3 Suppl):S108-28. PubMed ID: 14563078
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.
Kobayashi T; Goto R; Ito K; Mitsumori K
Eur J Surg Oncol; 2007 Aug; 33(6):783-9. PubMed ID: 17408910
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
8. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
Gerson L; Lin OS
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
[TBL] [Abstract][Full Text] [Related]
9. Early detection of prostate cancer. What do we tell our patients?
Schröder FH; Erasmus MC
Can J Urol; 2006 Apr; 13 Suppl 2():37-42. PubMed ID: 16672127
[TBL] [Abstract][Full Text] [Related]
10. [Screening for occult malignancies (breast, colorectum, prostate) beyond the usual age limits].
Rouësse J; Fourme E; Dehe S; Brain E
Bull Acad Natl Med; 2007 Feb; 191(2):287-99. PubMed ID: 17969549
[TBL] [Abstract][Full Text] [Related]
11. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
[TBL] [Abstract][Full Text] [Related]
12. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
13. Impact of age on screening and surveillance for primary liver cancer.
Patel T; Dangell C; Maheshwari S
Am J Gastroenterol; 2006 Apr; 101(4):768-74. PubMed ID: 16494589
[TBL] [Abstract][Full Text] [Related]
14. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
15. The routine use of high-resolution immunological screening of recipients of primary deceased donor kidney allografts is cost-effective.
McLaughlin K; Manns B; Nickerson P
Transplantation; 2006 May; 81(9):1278-84. PubMed ID: 16699455
[TBL] [Abstract][Full Text] [Related]
16. [Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?].
Kranjcević K; Marković BB
Acta Med Croatica; 2007 Feb; 61(1):45-8. PubMed ID: 17593640
[TBL] [Abstract][Full Text] [Related]
17. The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF.
Woodward RM; Brown ML; Stewart ST; Cronin KA; Cutler DM
Cancer; 2007 Dec; 110(11):2511-8. PubMed ID: 17955504
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
[TBL] [Abstract][Full Text] [Related]
19. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
Etzioni R; Gulati R; Falcon S; Penson DF
Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
